- Home
- FAMI vs SCNI Comparison
FAMI vs SCNI Comparison
Compare FAMI & SCNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FAMI
- SCNI
- Stock Information
- Founded
- FAMI 2015
- SCNI 2003
- Country
- FAMI China
- SCNI Israel
- Employees
- FAMI N/A
- SCNI N/A
- Industry
- FAMI Packaged Foods
- SCNI Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- FAMI Consumer Staples
- SCNI Health Care
- Exchange
- FAMI Nasdaq
- SCNI Nasdaq
- Market Cap
- FAMI 3.1M
- SCNI 3.5M
- IPO Year
- FAMI 2018
- SCNI N/A
- Fundamental
- Price
- FAMI $0.32
- SCNI $3.34
- Analyst Decision
- FAMI
- SCNI
- Analyst Count
- FAMI 0
- SCNI 0
- Target Price
- FAMI N/A
- SCNI N/A
- AVG Volume (30 Days)
- FAMI 300.7K
- SCNI 8.1K
- Earning Date
- FAMI 01-27-2025
- SCNI 11-22-2024
- Dividend Yield
- FAMI N/A
- SCNI N/A
- EPS Growth
- FAMI N/A
- SCNI N/A
- EPS
- FAMI 0.13
- SCNI 8.20
- Revenue
- FAMI $86,261,500.00
- SCNI $452,000.00
- Revenue This Year
- FAMI N/A
- SCNI N/A
- Revenue Next Year
- FAMI N/A
- SCNI N/A
- P/E Ratio
- FAMI $2.44
- SCNI $0.41
- Revenue Growth
- FAMI N/A
- SCNI N/A
- 52 Week Low
- FAMI $0.17
- SCNI $2.23
- 52 Week High
- FAMI $2.35
- SCNI $8.92
- Technical
- Relative Strength Index (RSI)
- FAMI 57.12
- SCNI 48.26
- Support Level
- FAMI $0.27
- SCNI $3.20
- Resistance Level
- FAMI $0.33
- SCNI $3.54
- Average True Range (ATR)
- FAMI 0.03
- SCNI 0.15
- MACD
- FAMI 0.00
- SCNI -0.00
- Stochastic Oscillator
- FAMI 79.14
- SCNI 40.00
About FAMI Farmmi Inc.
Farmmi Inc is a supplier of agricultural products. The products of the company are Shiitake Mushroom, Mu Er Mushroom and other edible fungi and other agricultural products. The majority of products are sold in mainland China.
About SCNI Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Ltd is a biopharmaceutical company focused on developing, manufacturing and commercializing products for the prevention and treatment of infectious diseases and other illnesses. It has executed eight clinical trials in seven countries, around 12,400 participants in the Phase 3 trial of its vaccine candidate and has built a GMP biologics manufacturing facility for biopharmaceutical products. The company is aiming to develop a pipeline of diversified and commercially viable products and platforms beginning with a nanosized antibody (NanoAb) pipeline.